Previous case reports have linked RET fusions, such as CCDC6-RET, TRIM24-RET, NCOA4-RET and ERC1-RET, to osimertinib resistance in EGFR-mutated NSCLC patients [35–39]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.